Verteporfin (Visudyne)

A benzoporphyrin derivative that is used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION.

Also Known As:

Visudyne; 18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester; BPD Verteporfin; BPD-MA; Benzoporphyrin Derivative Monoacid Ring A; Verteporphin

Networked: 1109 relevant articles (148 outcomes, 199 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bressler, Neil M: 23 articles (01/2022 - 01/2002)
2.	Hasan, Tayyaba: 23 articles (01/2022 - 03/2003)
3.	Schmidt-Erfurth, Ursula: 21 articles (08/2014 - 09/2002)
4.	Pogue, Brian W: 19 articles (01/2020 - 05/2002)
5.	Lai, Timothy Y Y: 16 articles (02/2021 - 09/2003)
6.	Bressler, Susan B: 14 articles (01/2022 - 10/2002)
7.	Miller, Joan W: 14 articles (01/2017 - 07/2002)
8.	Kaiser, Peter K: 13 articles (11/2022 - 03/2003)
9.	Chen, Bin: 13 articles (01/2020 - 03/2003)
10.	Slakter, Jason S: 12 articles (05/2012 - 02/2002)

Related Diseases

1.	Choroidal Neovascularization 05/01/2001 - "Other secondary outcomes, including visual acuity letter score worse than 34 (approximate Snellen equivalent of 20/200 or worse), mean change in visual acuity letter score, development of classic choroidal neovascularization, progression of classic choroidal neovascularization and size of lesion, favored the verteporfin-treated group at both the month 12 and month 24 examination for both the entire study group and the subgroup of cases with occult with no classic choroidal neovascularization at baseline. " 07/01/2007 - "More over the quality assurance regulations for the photodynamic treatment of choroidal neovascularizations with Verteporfin were modified including the treatment of occult lesions and implementing a simplified classification of extra- and subfoveal lesions. " 01/01/2006 - "Nineteen consecutive patients with predominantly classic choroidal neovascularization (CNV) in AMD were treated with 6 mg/m2 verteporfin given as bolus infusion. " 05/01/2004 - "[Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization. " 06/01/2003 - "As of this writing, the Food and Drug Administration is requiring additional data before verteporfin is approved for treatment of occult subfoveal choroidal neovascularization. "
2.	Macular Degeneration (Age-Related Maculopathy) 01/01/2021 - "The full dose of verteporfin used in CSC was 6 mg/m2, which was used in patients with neovascular age-related macular degeneration. " 01/01/2020 - "Moreover, our search of the Food and Drug Administration-approved drugs for those targeting GSC mitochondria revealed that verteporfin (Visudyne® ), a drug approved for macular degeneration, was a novel GSC-specific cytotoxic compound that reduced OXPHOS activity. " 01/01/2020 - "Verteporfin, an FDA approved drug, is used for the treatment of age-related macular degeneration. " 01/01/2019 - "Verteporfin is a benzoporphyrin derivative that is used clinically for photodynamic treatment of macular degeneration. " 11/17/2017 - "In the current, we investigated the ability of a repositioned drug verteporfin (VP), originally a treatment for macular degeneration, to inhibit GC cell growth. "
3.	Central Serous Chorioretinopathy 09/01/2009 - "On the basis of the results of this study and available information regarding the expected rate of spontaneous resolution, 30% verteporfin dose seems to be safe and effective in the treatment of acute central serous chorioretinopathy." 06/01/2023 - "Anatomical and functional impact of verteporfin shortage in patients with chronic central serous chorioretinopathy." 05/19/2023 - "Impact of the ongoing worldwide shortage of verteporfin (Visudyne®) on the visual function of patients with chronic central serous chorioretinopathy." 01/01/2013 - "Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy." 12/01/2012 - "Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy."
4.	Neoplasms (Cancer) 10/06/2015 - "Furthermore, verteporfin suppressed the proliferation of other cancer cell lines even in the absence of YAP1, suggesting that verteporfin may be effective against multiple types of solid cancers. " 01/01/2016 - "As verteporfin has shown anti-neoplastic activity in several types of cancers, here we hypothesized and investigated the efficacy of verteporfin against UM cells without light activation. " 01/01/2023 - "This is the first study to demonstrate that verteporfin-mediated inhibition of YAP leads to diminished tumorigenicity in lung and breast spinal metastatic cancer cells. " 01/01/2023 - "Animal studies used a subcutaneous xenograft mouse model to assess the use of systemic intraperitoneal verteporfin (IP-VP) and intratumoral verteporfin microparticles (IT-VP) to inhibit the tumorigenicity of lung and breast spinal metastatic tumors from primary patient-derived tissue. " 10/01/2022 - "Our study showed that verteporfin reduced tumor cell growth and enhanced apoptosis of human CCA tumor cells in vitro in a dose-dependent fashion. "
5.	Polypoidal Choroidal Vasculopathy 09/01/2010 - "The purpose of this study was to evaluate the efficacy of verteporfin photodynamic therapy on the treatment of polypoidal choroidal vasculopathy. " 02/01/2012 - "To study the effects of photodynamic therapy using verteporfin in the treatment of patients with subfoveal polypoidal choroidal vasculopathy (PCV). " 10/01/2002 - "To study the effects of photodynamic therapy using verteporfin in the treatment of patients with subfoveal polypoidal choroidal vasculopathy (PCV). " 08/01/2015 - "To evaluate the 3-year outcome in eyes with polypoidal choroidal vasculopathy (PCV) treated with photodynamic therapy with verteporfin. " 09/01/2010 - "Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up."

Related Drugs and Biologics

1.	1-phenyl-3,3-dimethyltriazene (PDT)
2.	Verteporfin (Visudyne)
3.	Ranibizumab (Lucentis)
4.	Photosensitizing Agents (Photosensitizers)
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Bevacizumab (Avastin)
7.	Triamcinolone Acetonide (Azmacort)
8.	Retinaldehyde (Retinal)
9.	Proteins (Proteins, Gene)
10.	Indocyanine Green (Cardio-Green)

Related Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy)
2.	Therapeutics
3.	Lasers (Laser)
4.	Intravitreal Injections
5.	Induced Hyperthermia (Thermotherapy)